Evidence map›Paper›PMID 41340912›Full record

ArticleMaterials today. Bio2025

Ruthenium coordinated nanohybrids modulate tumor microenvironment and potentiate amplified phototherapy augmented immunotherapy of hypoxic tumor.

Jingyao Li, Wenzhi Zhu, Qibao Zheng, Huixi Yi, Liyou Guo, Zhixiong Zhan, Nannan Fu, Muhammad Rizwan Younis, Chengzhi Jin, Junqiu Zhai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingyao LiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Wenzhi ZhuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Qibao ZhengGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Huixi YiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Liyou GuoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Zhixiong ZhanGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Nannan FuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Muhammad Rizwan YounisDepartment of Chemical and Biomolecular Engineering, University of California - Los Angeles, Los Angeles, CA, 90095, United States.
Chengzhi JinGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Junqiu ZhaiSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Dong-Yang ZhangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxic tumor microenvironment (TME) greatly limits the efficacy of photodynamic therapy (PDT) and immunotherapy. Additionally, small molecule phototherapeutic agents not only require delivery vectors due to their poor water solubility, but also suffer from poor photostability. Herein, we present a synergy of nanocatalysts-amplified PDT, sustained photothermal therapy (PTT) and robust immunotherapy for eliminating hypoxic solid tumor and preventing distant tumor metastasis by constructing the ruthenium coordinated nanohybrids (defined as RuIP) consisting of ruthenium (Ru) ions, phototherapeutic agent (IR825), and polyvinylpyrrolidone (PVP). The coordination driven self-assembly of IR825 with Ru improves the photostability of IR825 and endows it i) with high catalytic O

Indexed as

HypoxiaImmunotherapyPhotodynamic therapyPhotothermal therapyRutheniumTumor microenvironment

Identifiers

PMID41340912
PMCPMC12671372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.